Ken Griffin Aravive, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	SELL	$0.11 - $1.76 $2,937 - $46,992	-26,700 Reduced 78.3%	7,400 $0
Q2 2023 Aug 14, 2023	SELL	$1.25 - $1.92 $67,500 - $103,680	-54,000 Reduced 61.29%	34,100 $42,000
Q1 2023 May 15, 2023	SELL	$1.29 - $2.46 $4,257 - $8,118	-3,300 Reduced 3.61%	88,100 $176,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $1.83 $109,680 - $167,262	91,400 New	91,400 $120,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.